Clinical trial · Observational
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
Genetic Analysis of Toxicity Associated With High-Dose Melphalan
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The original PI on this study left VICC, thus study was closed.
Summary
Brief summary (as posted)
RATIONALE: Studying blood or mouthwash samples in the laboratory from patients receiving melphalan for cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and help predict how patients will respond to treatment. PURPOSE: This clinical trial is studying common genetic mutations related to mucositis in patients with multiple myeloma receiving high-dose melphalan.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mucositis | — | UNRESOLVED | — |
| Multiple Myeloma and Plasma Cell Neoplasm | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Retrospective sample
- description
- People who have been diagnosed with multiple myeloma and have received high-dose melphalan.
- interventionNames
- Other: laboratory biomarker analysis
- label
- Prospective sample
- description
- People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan.
- interventionNames
- Other: laboratory biomarker analysis
Primary outcomes (2)
- measure
- Association between single nucleotide polymorphisms (SNPs) in genes that encode the melphalan transporters and development and/or severity of mucositis
- timeFrame
- 4 weeks
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of multiple myeloma * Receiving treatment with high-dose melphalan for an autologous stem cell transplantation at any of these facilities: * Vanderbilt University Medical Center * Nashville Veteran's Administration Medical Center (VAMC) * Seattle VAMC * San Antonio VAMC PATIENT CHARACTERISTICS: * Not pregnant PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No palifermin
References
Publications (0)
Data not yet available